Business Management Articles | Page 2

Experts Discuss Ways to Remove Barriers to Optimal Management of CINV
Despite the widespread availability of antiemetic regimens, between 30% and 50% of patients receiving chemotherapy experience treatment-related nausea and/or vomiting.
There are certain commonly used terms in the realm of oncology that may result in unintended consequences and should be considered carefully before being employed in conversation or in writing.
More than 2 years after the passage of the Medicare Access and CHIP Reauthorization Act of 2015, the progression toward value-based care has challenged oncologists to assume an unprecedented degree of accountability for the well-being and holistic care of their patients.
Congressional "right-to-try" legislation could make investigational drugs available to desperately ill patients sooner in the trials process, but there are substantial risks.
A caseload management tool developed at the Mitchell Cancer Institute at the University of South Alabama offers a comprehensive portrait of a patient's condition that helps oncology nurse navigators to allocate their time and resources efficiently and enables managers to optimize patient care by assigning appropriate caseloads.
The FDA has approved a new breast-specific stereotactic body radiotherapy device known as GammaPod as a treatment for patients with breast cancer, based on findings from a 17-patient study.
$1.5 Trillion Tax Plan Heads to White House for Signature
The consolidated tax bill that now goes to President Trump’s desk for a signature carries with it dire warnings from oncology interest groups that access to care will suffer under the federal spending cutbacks that are expected to result.
FDA Grants Bevacizumab Full Approval for Glioblastoma
The FDA has granted bevacizumab a full approval for the treatment of adult patients with glioblastoma that progressed following prior therapy.
FDA Approves Trastuzumab Biosimilar
The FDA has approved the trastuzumab (Herceptin) biosimilar MYL-1401O (Ogivri; trastuzumab-dkst), which now has has approved indications for HER2-positive patients with breast or metastatic gastric or gastroesophageal junction adenocarcinoma.
Plan Now for MIPS Reporting in 2018
The end of the year is always hectic for oncology practices, but 2017 is proving exceptionally busy as CMS' Quality Payment Program transitional year comes to a close.
Publication Bottom Border
Border Publication